Metraipolis › archive › dc_35da299332a7

Clinical outcomes and toxicity in metastatic breast cancer patients treated with first or second-line cyclin-dependent kinase (CDK) 4/6 inhibitors and… — Europe PMC PMID:42495102

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42495102
DOI
10.11604/pamj.2026.53.121.49258
License (as archived)
solo-consultazione
Archived
2026-11-04T19:55:46.615Z
SHA-256 of the archived text
69af8d0fbf632a68a72b91bd6d686a6c6ea596cf0f602ee24f817db384f871b6
Stable URL of this page
https://metraipolis.com/documento/dc_35da299332a7

How to cite

Clinical outcomes and toxicity in metastatic breast cancer patients treated with first or second-line cyclin-dependent kinase (CDK) 4/6 inhibitors and… — Europe PMC PMID:42495102 — Europe PMC (en), https://europepmc.org/article/MED/42495102 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_35da299332a7 (Metraipolis archive dc_35da299332a7, sha256 69af8d0fbf632a68a72b91bd6d686a6c6ea596cf0f602ee24f817db384f871b6)
BibTeX
@misc{dc35da299332a7,
  title = {Clinical outcomes and toxicity in metastatic breast cancer patients treated with first or second-line cyclin-dependent kinase (CDK) 4/6 inhibitors and… — Europe PMC PMID:42495102},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42495102},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_35da299332a7; sha256 69af8d0fbf632a68a72b91bd6d686a6c6ea596cf0f602ee24f817db384f871b6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42495102. Agents can read the archived copy with the MCP tool read_document.